1. Scrip
  2. >>Business

Lilly Pays KeyBioscience $55m Up Front to Expand Its Early Diabetes Pipeline

 
• By Mandy Jackson

Lilly nabbed multiple molecules for its early-stage diabetes portfolio via a $55m-plus partnership with KeyBioscience, making sure that the big pharma's pipeline continues to add products to its largest franchise.

Diabetes

Eli Lilly & Co. will pay KeyBioscience AG $55m plus undisclosed milestone fees and tiered royalties to work on dual agonists of two well-known targets in the treatment of metabolic disorders, including diabetes – the biggest and increasingly the most important franchise in Lilly's portfolio.

Growth in Lilly's diabetes franchise will offset declining sales of drugs for central nervous system (CNS) diseases, which historically has...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Novartis Secures Approval For First Malaria Therapy for Babies

 
• By Kevin Grogan

Coartem Baby to be rolled out in eight African countries in the autumn.

Could Apogee Rival Regeneron/Sanofi, Lilly After Phase II Eczema Data Win?

 
• By Manas Mishra

Apogee Therapeutics reports data from Phase II APEX trial of its long-acting antibody against atopic dermatitis, showing similar efficacy to Regeneron/Sanofi’s Dupixent and Eli Lilly’s Ebglyss.

Finance Watch: A Mini-Surge In Follow-On Offerings Follows Positive Updates

 
• By Mandy Jackson

Public Company Edition: A breakthrough designation, data and deals prompted big follow-on public offerings in late June and early July, including $402.5m for Cidara, $250.8m for Kymera and $230m for Dyne. Also, Revolution Medicines accessed up to $2bn from Royalty Pharma.